Evidence map›Paper›PMID 30412730›Full record

ArticleJournal of neuroscience methods2019

Functional assessments through novel proteomics approaches: Application to insulin/IGF signaling in neurodegenerative disease'.

Srinivas Ayyadevara, Akshatha Ganne, Rachel D Hendrix, Meenakshisundaram Balasubramaniam, Robert J Shmookler Reis, Steven W Barger

Open access · greenAbstract read
In one paragraph

Article in Journal of neuroscience methods, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Role of the Insulin-like Growth Factor System in Neurodegenerative Disease.International journal of molecular sciences · 2024
    Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Srinivas AyyadevaraCentral Arkansas Veterans Healthcare System, Little Rock, AR, 72205, United States; Department of Geriatrics, University of Arkansas for Medical Sciences, Little Rock, AR 72205, United States. Electronic address: AyyadevaraSrinivas@uams.edu.
Akshatha GanneDepartment of Geriatrics, University of Arkansas for Medical Sciences, Little Rock, AR 72205, United States; BioInformatics Program, University of Arkansas for Medical Sciences, Little Rock, AR 72205, United States.
Rachel D HendrixDepartment of Neurobiology & Developmental Sciences, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, United States.
Meenakshisundaram BalasubramaniamDepartment of Geriatrics, University of Arkansas for Medical Sciences, Little Rock, AR 72205, United States.
Robert J Shmookler ReisCentral Arkansas Veterans Healthcare System, Little Rock, AR, 72205, United States; Department of Geriatrics, University of Arkansas for Medical Sciences, Little Rock, AR 72205, United States; BioInformatics Program, University of Arkansas for Medical Sciences, Little Rock, AR 72205, United States; Department of Biochemistry & Molecular Biology, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, United States.
Steven W BargerCentral Arkansas Veterans Healthcare System, Little Rock, AR, 72205, United States; Department of Geriatrics, University of Arkansas for Medical Sciences, Little Rock, AR 72205, United States; Department of Neurobiology & Developmental Sciences, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, United States. Electronic address: BargerStevenW@uams.edu.
Central Arkansas Veterans Healthcare System · USUniversity of Arkansas for Medical Sciences · US

Funding

Understanding Hesitant AdoptersP20GM103429 · NIGMS · UNIV OF ARKANSAS FOR MED SCIS · PI Lawrence E Cornett, JERRY WARE · 2012 to 2026
$60.9M
THE APOE-APP AXIS IN ALZHEIMER PATHOGENESISP01AG012411 · NIA · UNIV OF ARKANSAS FOR MED SCIS · PI GRIFFIN, SUE TILTON · 1995 to 2020
$25.0M
Inference of Common Pathways Underlying Neurodegeneration & Other Age-Progressive DiseasesR01AG062254 · NIA · UNIV OF ARKANSAS FOR MED SCIS · PI AYYADEVARA, SRINIVAS, SHMOOKLER REIS, ROBERT JOSEPH · 2018 to 2022
$1.9M
Analysis and Therapy of Age-Dependent Proteostasis Failure in NeurodegenerationI01BX001655 · VA · CENTRAL ARKANSAS VETERANS HLTHCARE SYS · PI SHMOOKLER REIS, ROBERT JOSEPH · 2013 to 2022
–
BLRD VA I01 BX001655BLRD VA IK6 BX004851NIA NIH HHS P01 AG012411NIA NIH HHS R01 AG062254NIGMS NIH HHS P20 GM103429
6 · The paper itself

Abstract

backgroundEvents that instigate disease may involve biochemical events distinct from changes in the steady-state levels of proteins. Even chronic degenerative disorders appear to involve changes such as post-translational modifications. NEW

methodWe have begun a series of proteomics analyses on proteins that have been fractionated by functional status. Because Alzheimer's disease (AD) is associated with metabolic perturbations such as Type-2 diabetes, fractionation hinged on binding to phosphatidylinositol trisphosphate (PIP3), key to insulin/insulin-like growth factor signaling. We compared mice on normal chow to counterparts subjected to diet-induced obesity (DIO) or to mice expressing human Aβ1-42 from a transgene.

resultsThe prevailing phenotypic finding in either experimental group was loss of PIP3 binding. Of the 1228 proteins that showed valid PIP3 binding in any group of mice, 55% exhibited a significant quantitative difference in the number of spectral counts as a function of DIO, 63% as function of the Aβ transgene, and 79% as a function of either variable. There was remarkable overlap among the proteins altered in the two experimental groups, and pathway analysis indicated effects on proteostasis, apoptosis, and synaptic vesicles. COMPARISON WITH EXISTING

methodsMost proteomics approaches only identify differences in the steady-state levels of proteins. Our overlay of a functional distinction permits new levels of discovery that may achieve novel insights into physiology in an unbiased and inclusive manner.

conclusionsProteomics analyses have revolutionized the discovery phase of biomedical research but are conventionally limited in scope. The creative use of fractionation prior to proteomic discovery is likely to provide important insights into AD and related disorders.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesAnimalsAnimals, Genetically ModifiedBrainCaenorhabditis elegansCarrier ProteinsDiet, WesternHumansInsulinMaleMembrane ProteinsMice, TransgenicObesityPeptide FragmentsPhosphatidylinositol PhosphatesAmyloid beta-Peptidesamyloid beta-protein (1-42)Carrier ProteinsInsulinMembrane ProteinsPeptide FragmentsPhosphatidylinositol PhosphatesSomatomedinsAlzheimer’s diseaseAmyloid β-peptideInsulinInsulin-like growth factorPhosphatidylinositol trisphosphateProteomicsTransgenic mouseWestern diet

Identifiers

PMID30412730
PMCPMC6451872
OpenAlexW2899605184

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.